Navigation Links
Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
Date:4/3/2008

-- generate cash,

-- identify, finance and enter into business relationships and

acquisitions.

Other factors include uncertainties and risks related to:

-- new product development, commercialization, manufacturing and market

acceptance of new products,

-- marketing acceptance of existing products in new markets,

-- research and development activities, including failure to demonstrate

clinical efficacy,

-- delays by regulatory authorities, scientific and technical advances by

Escalon or third parties,

-- introduction of competitive products,

-- third party reimbursement and physician training, and

-- general economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Escalon's report on Form 10- K, and its other filings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.


'/>"/>
SOURCE Escalon Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Escalon(R) Announces Executive Promotions
2. Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System
3. Escalon(R) Reports First Quarter Fiscal 2008 Results
4. Escalon(R) Reports Financial Results for 2007 Fiscal Year
5. NUCRYST Announces Senior Management Change
6. Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008
7. Medical Records Institute Announces New TEPR Award for EMRs Best Meeting Medicolegal Requirements
8. East Ridge Retirement Village Announces Enhancement Plan
9. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index
10. The Quantum Group Announces Increased Patient Enrollment Following Medicare Advantage Open Enrollment Period
11. Selective Insurance Group Announces Officer Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 2Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 3Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 2Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 3Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 4Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 5Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 2Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 3Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 4Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 5Health News:NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy 2Health News:NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy 3Health News:AIUM gears up for 2010 Annual Convention in San Diego, Calif. 2
Breaking Medicine Technology:National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2PRA International Hosts an Infectious Diseases Audio Conference 2PRA International Hosts an Infectious Diseases Audio Conference 3Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Pioneer 28R 29 Surgical Technology Inc Receives Prestigious Spine Technology Awards 6722 1Pioneer 28R 29 Surgical Technology Inc Receives Prestigious Spine Technology Awards 6722 2Upsher Smith Announces Milestone in Development of CNS Strategy 6718 1Upsher Smith Announces Milestone in Development of CNS Strategy 6718 2Honeywell and Pro Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 6714 1Honeywell and Pro Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 6714 2Honeywell and Pro Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 6714 3
Other Medicine Technology:Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 9California Stem Cell Agency Exaggerated Its Role in Funding Key Research 2